Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIGILANT: Depemokimab in COPD With Type 2 Inflammation
NCT07177339Phase 3Recruiting
- Sponsor
- GSK
- Start
- Oct 2025
- Primary completion
- Apr 2029
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of depemokimab in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Oct 2025; status: recruiting.
02
Drugs
depemokimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07177339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07177339.